Adjunct Faculty
Adjunct Faculty are scientists or others who are employed outside of the school but have a specific, mutually beneficial role to Yale School of Medicine department programs.
Adjunct rank detailsRory Shallis, MD
Assistant Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Assistant Professor Adjunct
Biography
Dr. Shallis received his MD from Rutgers-Robert Wood Johnson Medical School, completed his residency training at Brown University-Rhode Island Hospital and fellowship training at Yale-New Haven Hospital.
He is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He also participated in the K12 Calabresi Immuno-Oncology Training Program and currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS.
Dr. Shallis also maintains research interest in epidemiological, outcomes and effectiveness research as it pertains to the hematologic malignancies with a goal of identifying barriers to effective care and ultimately strategies to improve the outcomes of patients with these malignant diseases. Dr. Shallis conducts research with the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale University.
Dr. Shallis has presented his research at multiple regional, national and international meetings and is a member of the National Comprehensive Cancer Network (NCCN) clinical guidelines for MDS and AML panels. He is an author on more than 75 peer-reviewed publications and book chapters, most of which as first author and has served as an ad hoc reviewer for many journals including Leukemia, Haematologica, Blood Advances, Leukemia Research, Leukemia & Lymphoma, Acta Haematologica, Hematology, Therapeutic Advances in Hematology, Expert Review of Hematology, BMC Hematology, eJHaem and Future Oncology among others.
Last Updated on November 17, 2022.
Appointments
Medical Oncology and Hematology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Leukemia & Lymphoma Program
- Medical Oncology and Hematology
Education & Training
- Fellowship
- Yale - New Haven Hospital (2020)
- Internship
- Brown University - Rhode Island Hospital (2017)
- Residency
- Brown University - Rhode Island Hospital (2017)
- MD
- Rutgers University - Robert Wood Johnson Medical School (2014)
- BA
- Rutgers College, Cell Biology & Neuroscience Psychology (2010)
Research
Copy Link
Overview
Medical Research Interests
Epidemiology; Leukemia; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders
ORCID
0000-0002-8542-2944
Research at a Glance
Yale Co-Authors
Frequent collaborators of Rory Shallis's published research.
Publications Timeline
A big-picture view of Rory Shallis's research output by year.
Research Interests
Research topics Rory Shallis is interested in exploring.
Amer Zeidan, MBBS
Jan Philipp Bewersdorf, MD, FACP
Nikolai Podoltsev, MD, PhD
Maximilian Stahl, MD
Rong Wang, PhD
Xiaomei Ma, PhD
146Publications
2,945Citations
Myelodysplastic Syndromes
Myeloproliferative Disorders
Leukemia
Myelodysplastic-Myeloproliferative Diseases
Publications
2025
AML-649: Inferior Outcomes in Black Patients With AML: Impact of Genomics and Clinical Risk Factors
Joshi U, Zahra F, Patel P, Yadav S, Al Ali N, Thompson Z, Pakasticali N, Song J, Shallis R, Xie Z, Yun S, Kuykendall A, Padron E, Walker A, Sallman D, Komrokji R, Lancet J, Hussaini M, Chan O. AML-649: Inferior Outcomes in Black Patients With AML: Impact of Genomics and Clinical Risk Factors. Clinical Lymphoma Myeloma & Leukemia 2025, 25: s449. DOI: 10.1016/s2152-2650(25)01710-0.Peer-Reviewed Original ResearchConceptsStem cell transplantationOverall survivalECOG statusBlack patientsWhite patientsMyeloid malignanciesAllogeneic stem cell transplantationNewly diagnosed AMLResults Median agePredictors of survivalKaplan-Meier curvesClinical risk factorsMultivariate Cox modelMoffitt Cancer CenterOS ratesBM blastsExtramedullary diseaseInferior survivalTP53 mutationsPrimary myelofibrosisAML cohortPrognostic factorsCell transplantationNPM1 mutationsMedian ageMDS-1056: Outcomes of Hypomethylating Agent-Based Therapy in Patients With Myelodysplastic Syndrome With Fibrosis
Huetteman A, Al-Ali N, Sallman D, Padron E, Kuykendall A, Chan O, Xie Z, Walker A, Yun S, Shallis R, Reynolds S, Sweet K, Komrokji R, Lancet J. MDS-1056: Outcomes of Hypomethylating Agent-Based Therapy in Patients With Myelodysplastic Syndrome With Fibrosis. Clinical Lymphoma Myeloma & Leukemia 2025, 25: s631. DOI: 10.1016/s2152-2650(25)02059-2.Peer-Reviewed Original ResearchConceptsOverall response rateDisease-free survivalOverall survivalMDS-FHMA therapyMyelodysplastic syndromeObservational studyObservational study of patientsResponse ratePeripheral blood blastsBone marrow blastsHypomethylating agent-based therapyAgent-based therapyStudy of patientsMedian OSBlood blastsMarrow blastsCR ratePrognostic subgroupsMDS subgroupTP53 inactivationInferior outcomesBaseline demographicsPoor outcomeTreatment strategiesPOSTER: MDS-1056 Outcomes of Hypomethylating Agent-Based Therapy in Patients With Myelodysplastic Syndrome With Fibrosis
Huetteman A, Al-Ali N, Sallman D, Padron E, Kuykendall A, Chan O, Xie Z, Walker A, Yun S, Shallis R, Reynolds S, Sweet K, Komrokji R, Lancet J. POSTER: MDS-1056 Outcomes of Hypomethylating Agent-Based Therapy in Patients With Myelodysplastic Syndrome With Fibrosis. Clinical Lymphoma Myeloma & Leukemia 2025, 25: s232. DOI: 10.1016/s2152-2650(25)00838-9.Peer-Reviewed Original ResearchPOSTER: AML-649 Inferior Outcomes in Black Patients With AML: Impact of Genomics and Clinical Risk Factors
Joshi U, Zahra F, Patel P, Yadav S, Al Ali N, Thompson Z, Pakasticali N, Song J, Shallis R, Xie Z, Yun S, Kuykendall A, Padron E, Walker A, Sallman D, Komrokji R, Lancet J, Hussaini M, Chan O. POSTER: AML-649 Inferior Outcomes in Black Patients With AML: Impact of Genomics and Clinical Risk Factors. Clinical Lymphoma Myeloma & Leukemia 2025, 25: s192. DOI: 10.1016/s2152-2650(25)00558-0.Peer-Reviewed Original ResearchSecond Malignancies among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib
Wang R, Stempel J, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Bewersdorf J, Mendez L, Ma X, Podoltsev N. Second Malignancies among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib. Blood Neoplasia 2025, 100159. DOI: 10.1016/j.bneo.2025.100159.Peer-Reviewed Original ResearchAltmetricConceptsSecond malignanciesMyeloproliferative neoplasmsOlder patientsEssential thrombocythemiaPolycythemia veraPhiladelphia chromosome-negative myeloproliferative neoplasmsDevelopment of second malignanciesRisk of non-melanoma skin cancerEnd Results Medicare-linked databaseNon-melanoma skin cancerMedian Follow-UpMedicare-linked databaseTherapy-related effectsRetrospective cohort analysisRisk of SMHazards regression modelsProportion of daysRuxolitinib exposureMedian ageFollow-upRuxolitinibCohort analysisSkin cancerPatientsMyelofibrosisLonger time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Yates S, Weiss J, Sneider A, Geramita E, Murthy G, Badar T, Im A, Lin C, Cheng W, Abaza Y, Swaroop A, Winer E, Litzow M, Atallah E, Patel A, Shallis R. Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Haematologica 2025 PMID: 40702896, DOI: 10.3324/haematol.2025.288085.Peer-Reviewed Original ResearchAltmetricConceptsTreatment start dateAcute myeloid leukemiaHypomethylating agentsOverall survivalEuropean LeukemiaNetMyeloid leukemiaAML disease biologyDiagnosis of acute myeloid leukemiaAML-directed therapyDiagnosis to initiationRetrospective cohort studyMyeloid malignanciesRisk diseaseSurvival outcomesOncologic emergencyCohort studyAcademic centersMulti-centerNeoplastic diseasePatientsDisease biologyRisk classificationDiagnosisLeukemiaSurvivalAvapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review
Getz T, Bakirhan K, Seropian S, Shallis R. Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review. Annals Of Hematology 2025, 104: 3889-3892. PMID: 40576687, PMCID: PMC12334448, DOI: 10.1007/s00277-025-06388-w.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsAcute myeloid leukemiaT(8;21) acute myeloid leukemiaDeep remissionKIT mutationsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationCore binding factor acute myeloid leukemiaHematopoietic stem cell transplantationTreatment of acute myeloid leukemiaFavorable risk diseaseStem cell transplantationTyrosine kinase inhibitorsT(8;21)Based chemotherapyOverall survivalSystemic mastocytosisCell transplantationRisk diseaseTargeted therapyCase reportKinase inhibitorsClinical challengeT(8;21Clinical investigationAvapritinibIntegrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab
Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances In Hematology 2025, 16: 20406207251347344. PMID: 40546817, PMCID: PMC12182606, DOI: 10.1177/20406207251347344.Peer-Reviewed Original ResearchThis study investigates the immune landscape of RNA splicing factor-mutant AML and MDS, showing no survival benefit from adding durvalumab to azacitidine treatment.Should we treat TP53-mutated high-risk myeloid neoplasms in older patients?
Badar T, E.l. Kettani M, Shah K, Jamy O, Shallis R, Diebold K, Coltoff A, Goldberg A, Patel A, Bewersdorf J, Foucar C, Abaza Y, Palmisiano N, DuVall A, Kota V, Zeidan A, Atallah E, Litzow M. Should we treat TP53-mutated high-risk myeloid neoplasms in older patients? Journal Of Clinical Oncology 2025, 43: 6538-6538. DOI: 10.1200/jco.2025.43.16_suppl.6538.Peer-Reviewed Original ResearchCitationsConceptsMedian overall survivalHigh-risk myeloid neoplasmsAllo-HCTDuration of responseTP53-MTHypomethylating agentsVariant allele frequencyOlder ptsMyeloid neoplasmsECOG-PSHR-MDSEastern Cooperative Oncology Group performance statusMedian duration of responseTP53 variant allele frequencyAllogeneic stem cell transplantationECOG-PS 0De novo AMLLong-term remissionStem cell transplantationLow-intensity therapyMulticenter observational studyProportion of ptsDisease-directed therapyMulti-center studyMPN-BPHeterogeneity in outcomes of TP53‐mutated myeloproliferative neoplasms based on disease phenotype and mutational status
Badar T, Foran J, Bewersdorf J, Wang Y, Coltoff A, Kettani M, Shah K, Oliva F, Lin C, Jamy O, Diebold K, Shallis R, Siddon A, Katkov D, Schoen A, Khan I, Foucar C, Atallah E, Goldberg A, Patel A. Heterogeneity in outcomes of TP53‐mutated myeloproliferative neoplasms based on disease phenotype and mutational status. British Journal Of Haematology 2025, 207: 683-686. PMID: 40400334, DOI: 10.1111/bjh.20187.Peer-Reviewed Original ResearchCitationsAltmetric
Academic Achievements & Community Involvement
Copy Link
Activities
activity National Comprehensive Cancer Network (NCCN) - Myelodysplastic Syndromes Guideline Panel
12/01/2020 - PresentCommitteesMemberactivity Older Adult AML Working Group - National Cancer Institute (NCI) Myeloid Precision Medicine Initiative
09/01/2020 - PresentPeer Review Groups and Grant Study SectionsMemberactivity ECOG-ACRIN Leukemia Committee
07/23/2020 - PresentCommitteesMemberactivity American Society of Hematology (ASH)
07/03/2017 - PresentProfessional OrganizationsMemberactivity American Society of Clinical Oncology (ASCO)
07/03/2017 - PresentProfessional OrganizationsMember
Honors
honor Top Overall Abstract
06/08/2020Regional AwardMyeloid Malignancies SymposiumDetailsUnited Stateshonor Hematology/Oncology Fellowship Program Research Award
06/01/2019Yale School of Medicine AwardYale Cancer CenterDetailsUnited States
News
Copy Link
News
- December 13, 2024Source: OncLive
How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD
- November 26, 2024
Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology Meeting
- May 01, 2024
Yale Department of Internal Medicine Faculty Promotions and Appointments (May 2024)
- March 25, 2024
Yale’s Post ASH Review
Get In Touch
Copy Link